GEKA Stock Chart & Stats
€0.86
€0.04(3.33%)
At close: 4:00 PM EST
€0.86
€0.04(3.33%)
Day’s Range― - ―
52-Week Range€0.70 - €1.09
Previous CloseN/A
Volume0.00
Average Volume (3M)110.00
Market Cap
€725.63M
Enterprise Value€23.20K
Total Cash (Recent Filing)€2.81B
Total Debt (Recent Filing)€4.73B
Price to Earnings (P/E)8.9
Beta0.29
Next Earnings
Jul 23, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.64
Shares Outstanding1,000,000,000
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)1.57
Price to Sales (P/S)0.99
P/FCF Ratio8.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.80Price Target Upside-7.29% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genomma Lab Internacional SAB de CV News
GEKA FAQ
What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?
Genomma Lab Internacional SAB de CV Class B lowest stock price was €0.70 and its highest was €1.09 in the past 12 months.
What is Genomma Lab Internacional SAB de CV Class B’s market cap?
Genomma Lab Internacional SAB de CV Class B’s market cap is €725.63M.
When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?
Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Jul 23, 2026 which is today.
How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?
Currently, no data Available
Is Genomma Lab Internacional SAB de CV Class B overvalued?
According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued.
Does Genomma Lab Internacional SAB de CV Class B pay dividends?
Genomma Lab Internacional SAB de CV Class B does not currently pay dividends.
What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?
Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.02.
How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?
Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.
What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?
Currently, no hedge funds are holding shares in DE:GEKA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genomma Lab Internacional SAB de CV Class B
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
GEKA Stock 12 Month Forecast
Average Price Target
€0.80
▼(-7.29% Downside)








